U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SAN FRANCISCO, April 10, 2017 -- Today Zephyr Health, the leading Insights-as-a-Service company, released a report entitled “Powering the Life Sciences Commercial Engine with Market Access Insights.” Based on results from a survey of 60 industry leaders working in market access, medical affairs, marketing and sales, the report examines the challenges with effective market access data integration between market access and commercial teams, and key opportunities to reengineer the business for the future.
According to this report, all survey respondents recognized the importance of a market access-driven commercial model, and the need to more effectively share data to gain any competitive advantage that a formulary change might offer. In fact, more than 40% of participants cite data integration and sharing as the biggest barrier to collaboration between managed markets and sales and marketing teams. Organizational silos and disparate technology solutions play a significant role in these challenges.
“It’s clear from the survey that the Life Sciences industry still needs solutions for effective pull-through by field sales for market access opportunities created by managed care teams” said Lance Scott, chief executive officer, Zephyr Health. “While pharmaceutical companies have a clear understanding of the power these insights can provide, in terms of commercial success, breaking down silos throughout the organization is essential to data integration of any kind. However, these efforts must be supplemented with technology that disseminates rich and predictive insights across the organization in order to stay ahead of competition.”
The “Powering the Life Sciences Commercial Engine with Market Access Insight” global survey examined the landscape for pharmaceutical companies seeking to bridge the insights gap between market access teams and other commercial functions. For more information, download a copy of the Zephyr Health report.
About Zephyr Health
Zephyr Health helps Life Sciences companies – pharmaceutical, biotech, medical device and diagnostics – engage the right physicians, accounts and institutions using insights from global health data. Zephyr Illuminate™ is a leading Insights-as-a-Service solution that integrates thousands of data sources to create precise and predictive insights. From pre-launch to product maturity, Life Sciences companies can make confident decisions faster with data-driven targeting and deep customer profiles.
Zephyr Health is a privately held company headquartered in San Francisco with offices in London, UK, and Pune, India. Zephyr Health is venture backed by Google Ventures, Kleiner Perkins Caufield & Byers, and Icon Ventures. For more information, please visit: www.zephyrhealth.com.
Media contact for Zephyr Health: [email protected]
